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Abstract
Background: Several genetic association studies have examined the relationships between single nucleotide
polymorphisms (SNPs) in the IL13 gene and eczema, and have provided contradictory results. We investigated the
relationship between the IL13 SNPs rs1800925 and rs20541 and the risk of eczema in Japanese young adult
women.
Methods: Included were 188 cases who met the criteria of the International Study of Asthma and Allergies in
Childhood (ISAAC) for eczema. Control subjects were 1,082 women without eczema according to the ISAAC
criteria, who had not been diagnosed with atopic eczema by a doctor and who had no current asthma as defined
by the European Community Respiratory Health Survey criteria. Adjustment was made for age, region of residence,
number of children, smoking, and education.
Results: The minor TT genotype of SNP rs1800925 was significantly associated with an increased risk of eczema in
the co-dominant model: the adjusted odds ratio was 2.19 (95% confidence interval: 1.03-4.67). SNP rs20541 was not
related to eczema. None of the haplotypes were significantly associated with eczema. Compared with women with
the CC or CT genotype of SNP rs1800925 who had never smoked, those with the TT genotype who had ever
smoked had a 2.85-fold increased risk of eczema, though the adjusted odds ratio was not statistically significant,
and neither multiplicative nor additive interaction was statistically significant.
Conclusions: Our findings suggest that the IL13 SNP rs1800925 is significantly associated with eczema in Japanese
young adult women. We could not find evidence for an interaction between SNP rs1800925 and smoking with
regard to eczema.
Background
In Japan, atopic eczema is a major public health pro-
blem not only among children but also among adults.
One study has reported atopic eczema prevalence values
of 10.9% and 7.8% among Japanese women in their 20s
and 30s, respectively [1]. The role of genetic and envir-
onmental risk factors in the development of atopic
eczema has gained interest.
Interleukin (IL)-13 is a central mediator of Th2 immune
responses [2]. IL-13 is expressed in acute and chronic
lesions and in unaffected skin from patients with atopic
eczema [3]. T cells and mast cells are important sources of
IL-13 in skin lesions from patients with atopic eczema [4].
The percentage of CD4
+ IL-13
+ T cells has been shown to
correlate significantly with the severity of atopic eczema in
children [5]. High IL-13 production by phytohaemaggluti-
nin- and house dust mite allergen Der p 1-stimulated cord
blood mononuclear cells has been associated with the
development of atopic eczema by the age of 3 years [6].
Several genetic association studies have examined rela-
tionships between single nucleotide polymorphisms
(SNPs) in the IL13 gene and eczema, and have provided
contradictory results [7-15]. Our recent study of Japanese
children aged 3 years showed that the minor TT geno-
type of SNP rs1800925 (-1024C/T) and the minor AA
genotype of SNP rs20541 (Arg110/130Glu) were signifi-
cantly related to an increased risk of eczema and that
perinatal smoking exposure did not interact with the 2
S N P si nt h ee t i o l o g yo fe c z e m a[ 1 5 ] .T h e s e2S N P sa r e
functional SNPs. Having established this, we wished to
investigate these issues in Japanese adults using data
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Methods
Study Population
The KOMCHS is an ongoing prospective prebirth cohort
study that investigates risk and preventive factors for
maternal and child health problems such as allergic disor-
ders. From April 2007 to March 2008, the KOMCHS
requested that 131 obstetric hospitals in Fukuoka Prefec-
ture, the largest prefecture on Kyushu Island in southern
Japan, with a total population of approximately 5.04 mil-
lion, provide as many pregnant women as possible with a
set of leaflets explaining the KOMCHS, an application to
participate in the study, and a self-addressed stamped
envelope in which to return the application. From May
2007 to March 2008, the KOMCHS also requested that 40
obstetric hospitals in Okinawa Prefecture, one of the
southernmost islands of Japan, with a total population of
almost 1.37 million, provide as many pregnant women as
possible with a comparable set of documents. Later, to
increase the sample size, pregnant women living in 6 pre-
fectures on Kyushu Island other than Fukuoka Prefecture,
with a total population of approximately 8.22 million,
were provided with comparable documents at 252 obste-
tric hospitals between August 2007 and March 2008. Preg-
nant women who intended to participate in the KOMCHS
returned the application form to the data management
center. By the end of the study, a total of 1757 pregnant
women between the 5th and 39th week of pregnancy had
given their fully informed consent in writing to participate
in the KOMCHS and had completed the baseline survey.
Around four months after delivery, 1492 women gave
informed consent to genotyping. The ethics committee of
the Faculty of Medicine, Fukuoka University, approved the
KOMCHS.
Selection of Cases and Controls
Women with eczema were identified based on the Interna-
tional Study of Asthma and Allergies in Childhood
(ISAAC) Phase One questionnaire [16]. Affirmative
answers to the following 3 questions were required: ‘Have
you ever had an itchy rash which was coming and going
for at least 6 months?’, ‘Have you had this itchy rash at
any time in the last 12 months?’ and ‘Has this itchy rash at
any time affected any of the following places: the folds of
the elbows, behind the knees, in front of the ankles, under
the buttocks, or around the neck, ears, or eyes?’ Eventually,
188 cases of eczema were identified.
Of the 1304 remaining participants who were therefore
eligible to serve as controls, 173 women were excluded
from the analysis because they answered ‘yes’ to the ques-
tion: ‘Have you ever been diagnosed by a physician as hav-
ing atopic eczema?’. Sixty-six were excluded who provided
a positive response to either of 2 situations: an asthma
attack during the last 12 months or current use of asthma
medication, with asthma as defined by the European Com-
munity Respiratory Health Survey [17]. Finally, 1 mother
was excluded because of missing data on smoking.
Because 18 mothers had both doctor-diagnosed atopic
eczema and current asthma, 1082 control subjects
remained for the final analysis.
DNA Extraction and Genotyping
Research technicians or subjects themselves collected buc-
cal specimens with BuccalAmp swabs (Epicenter Bio-
Technologies, Madison, WI, USA). Genomic DNA was
extracted using a QIAmp DNA mini kit (Qiagen, Inc.,
Valencia, CA, USA). Two SNPs from the IL13 gene were
used in this study: rs1800925 in the 5’ promoter region
and rs20541 in exon 4. Genotyping of the two IL13 poly-
morphisms was performed using pre-development Taq-
Man SNP Genotyping Assays (Applied Biosystems, Foster
City, CA, USA).
Statistical Analysis
Deviation from the Hardy-Weinberg equilibrium among
control subjects was evaluated by the chi-square test. Link-
age disequilibrium was investigated using Haploview soft-
ware version 4.1 [18]. Logistic regression analysis was used
to obtain the crude odds ratios (ORs) and 95% confidence
intervals (CIs) for eczema relative to the SNPs under
study. Multiple logistic regression analysis was used to
adjust for age, region of residence, number of children,
smoking, and education. The statistical power calculation
was performed using QUANTO version 1.2 [19]. Haplo-
types and their frequencies were inferred with the expecta-
tion maximization (EM) algorithm. For differences in
haplotype frequency between the case and control groups,
crude ORs and 95% CIs were estimated based on the fre-
quency of each haplotype relative to all other haplotypes
combined. The multiplicative interaction was tested using
a term of the product of two variables in a multiple logistic
regression model. Three measures were used to test the
additive interaction [20]: 1) relative excess risk due to
interaction (RERI), 2) attributable proportion due to inter-
action (AP), and 3) synergy index (S). RERI is the excess
risk due to an interaction relative to the risk without expo-
sure. AP refers to the attributable proportion of disease
that is due to an interaction among individuals with both
exposures. S is the excess risk from both exposures when
there is an additive interaction, relative to the risk from
both exposures without an interaction. RERI = 0, AP = 0,
or S = 1 means no interaction or strict additivity; RERI >
0, AP > 0, or S > 1 means positive interaction or more
than additivity; RERI < 0, AP < 0, or S < 1 means negative
interaction or less than additivity [21]. If any of the null
values (0 in RERI and AP or 1 in S) falls outside the 95%
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action is considered statistically significant. Details of the
method for the calculation of the additive interaction have
been described by Andersson et al. [20]. Excluding the cal-
culation of linkage disequilibrium and statistical power
calculation, all statistical analyses were performed using
STATA/SE software version 12.0 (StataCorp, College
Station, TX, USA).
Results
Compared with control subjects, women with eczema
were more likely to be younger (Table 1). There were
no differences between eczema cases and control sub-
jects with regard to region of residence, number of chil-
dren, smoking, and education.
IL13 SNPs rs1800925 and rs20541 were tested for devia-
tion from the Hardy-Weinberg equilibrium; there was no
deviation among control subjects (p = 0.10 and 0.83,
respectively). SNPs rs1800925 and rs20541 were in high
linkage disequilibrium (D’ = 0.84, r
2 = 0.37).
The frequency of the TT genotype of SNP rs1800925
was 5.3% in cases and 2.5% in control subjects (Table 2).
Compared to a reference group of subjects with the CC
genotype, women with the TT genotype had a signifi-
cantly increased risk of eczema, whereas no association
was found between the CT genotype and eczema in
crude analysis. Adjustment for confounders under inves-
tigation did not appreciably change the results: the
adjusted ORs for the CT and TT genotypes were 1.01
(95% CI: 0.71-1.42) and 2.19 (95% CI: 1.03-4.67), respec-
tively. In the recessive model, the TT genotype was sig-
nificantly positively associated with eczema: the adjusted
OR was 2.19 (95% CI: 1.04-4.63); however, no significant
relationship was observed in the additive or dominant
model. We could not find a significant association
between SNP rs20541 and eczema in any genetic model.
With respect to SNP rs20541, the statistical power calcu-
lation revealed that, using our sample size, we could
detect the gene-disease association for an OR of 1.397
with an accuracy of more than 80% under the log-addi-
tive model.
Four haplotypes were constructed, but none of these
were significantly associated with the risk of eczema
(Table 3).
Compared with women with the CC or CT genotype
of SNP rs1800925 who had never smoked, those with
t h eT Tg e n o t y p ew h oh a de v e rs m o k e dh a da2 . 8 5 - f o l d
increased risk of eczema, although the adjusted OR was
not statistically significant, and neither multiplicative
nor additive interaction was statistically significant
(Table 4).
The results of a sensitivity analysis restricted to cases
without current asthma as defined by the European
Community Respiratory Health Survey (n = 165) were
similar to those in the overall analysis: the adjusted OR
was 2.51 (95% CI: 1.18-5.36) for the TT genotype of SNP
rs1800925 and 1.33 (95% CI: 0.75-2.36) for the AA geno-
type of SNP rs20541 in the co-dominant model.
Discussion
Our previous study of Japanese children aged 3 years
observed that both IL13 SNPs rs1800925 and rs20541
were significantly associated with the risk of eczema [15].
Interestingly, in that study, after mutual adjustment for
SNPs rs1800925 and rs20541, the positive relationship
between SNP rs1800925 and eczema remained statisti-
cally significant, whereas the positive association between
SNP rs20541 and eczema completely disappeared [15].
The current results are in partial agreement with our pre-
vious findings. Another Japanese case-control study,
which included patients with atopic eczema aged 11-61
years, showed a significant association between SNP
Table 1 Characteristics of the study population
n (%) or mean (SD)
Variable Cases
(N = 188)
Controls
(N = 1,082)
P value*
Age, years 30.7 (4.6) 31.6 (4.2) 0.006
Region of residence (%) 0.50
Fukuoka Prefecture 112 (59.6) 610 (56.4)
Other than Fukuoka Prefecture in Kyushu 61 (32.5) 357 (33.0)
Okinawa Prefecture 15 (8.0) 115 (10.6)
Having one or more children (%) 107 (56.9) 669 (61.8) 0.20
Having ever smoked (%) 63 (33.5) 336 (31.1) 0.50
Education (%) 0.77
< 13 years 44 (23.4) 228 (21.1)
13-14 years 62 (33.0) 368 (34.0)
≥ 15 years 82 (43.6) 486 (44.9)
* c
2 test or t test.
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studies conducted in countries other than Japan, to our
knowledge, only 1 case-control study of Danish subjects
aged 17-66 years found a significant relationship between
SNP rs1800925 and atopic eczema [9]. In contrast, a null
association between SNP rs1800925 and eczema was
observed in studies of Canadian [10], US [11], and UK
[13] children as well as in a study of children aged 8-12
years from 13 countries [14] and a study of Taiwanese
young adults [12]. Two studies of German [7] and Cana-
dian [10] children found a significant association between
SNP rs20541 and eczema, whereas a relationship between
SNP rs20541 and eczema was ruled out in 2 studies of
US [11] and UK [13] children and in a study of Taiwa-
nese adults [12]. These discrepancies may be at least
partly explained by differences in genetic background of
the populations examined, definitions of eczema, and sta-
tistical power.
In a study in the Netherlands, subjects with the TT
genotype of SNP rs1800925 exhibited significantly
weaker relative inhibition of IL-13 production upon addi-
tional stimulation with anti-CD2 compared to those with
the CC or CT genotype [22]. Cameron and colleagues
have shown that the T allele of SNP rs1800925 enhanced
IL13 promoter activity in primary human and murine
CD4
+ Th2 lymphocytes through Yin-Yang 1-dependent
attenuation of STAT6-mediated promoter repression and
that mitogen-activated peripheral blood mononuclear
cells from pregnant women with the TT genotype of
SNP rs1800925 secreted significantly higher levels of IL-
13 compared with those from pregnant women with the
CC or CT genotype [23]. A laboratory study has shown
that the IL-13 Glu110 variant is significantly more active
than wild-type IL-13 in inducing STAT6 phosphorylation
and CD23 expression in primary human monocytes as
well as hydrocortisone-dependent IgE switching in
human B cells, and that the IL-13 Glu110 variant was
neutralized less effectively than wild-type IL-13 by a solu-
ble form of IL-13Ra2 [24].
A study in Germany reported that secondhand smoke
exposure increased IL-13 levels in children with asthma
[ 2 5 ] .I nas t u d yi nt h eU K ,as i g n i f i c a n ti n t e r a c t i o nw a s
found between SNP rs1800925 and smoking with respect
to the risk of allergy [26]. In our previous study, however,
Table 2 Odds ratios and 95% confidence intervals for eczema according to IL13 polymorphisms in Japanese women
SNP Model Genotype Cases n (%) Controls n (%) Crude OR (95% CI) Adjusted OR (95% CI)*
rs1800925 (N = 188) (N = 1,082)
Co-dominant CC 122 (64.9) 717 (66.3) 1.00 1.00
CT 56 (29.8) 338 (31.2) 0.97 (0.69-1.37) 1.01 (0.71-1.42)
TT 10 (5.3) 27 (2.5) 2.18 (1.03-4.61) 2.19 (1.03-4.67)
Additive 1.15 (0.87-1.52) 1.18 (0.89-1.56)
Dominant CC 122 (64.9) 717 (66.3) 1.00 1.00
CT + TT 66 (35.1) 365 (33.7) 1.06 (0.77-1.47) 1.10 (0.79-1.52)
Recessive CC + CT 178 (94.7) 1,055 (97.5) 1.00 1.00
TT 10 (5.3) 27 (2.5) 2.20 (1.04-4.61) 2.19 (1.04-4.63)
rs20541 (N = 188) (N = 1,081)
Co-dominant GG 85 (45.2) 536 (49.6) 1.00 1.00
GA 82 (43.6) 448 (41.4) 1.15 (0.83-1.60) 1.16 (0.84-1.62)
AA 21 (11.2) 97 (9.0) 1.37 (0.81-2.31) 1.44 (0.85-2.44)
Additive 1.16 (0.92-1.47) 1.19 (0.94-1.50)
Dominant GG 85 (45.2) 536 (49.6) 1.00 1.00
GA + AA 103 (54.8) 545 (50.4) 1.19 (0.87-1.63) 1.21 (0.89-1.66)
Recessive GG + GA 167 (88.8) 984 (91.0) 1.00 1.00
AA 21 (11.2) 97 (9.0) 1.28 (0.77-2.10) 1.34 (0.81-2.22)
* Adjusted for age, region of residence, number of children, smoking, and education.
Table 3 Haplotype analysis of rs1800925 and rs20541 in relation to eczema in Japanese women
Haplotype Haplotype structure Frequency n (%)
number rs1800925 rs20541 Cases (2N = 376) Controls (2N = 2,164) Crude OR (95% CI)*
1 C G 249 (66.2) 1,475(68.2) 0.92 (0.72-1.16)
2 C A 51 (13.6) 297 (13.7) 0.99 (0.70-1.37)
3 T G 3 (0.8) 47 (2.2) 0.36 (0.07-1.14)
4 T A 73 (19.4) 345 (15.9) 1.27 (0.95-1.69)
* Crude OR for each haplotype is relative to all other haplotypes combined.
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exposure and SNPs rs1800925 and rs20541 in the etiol-
ogy of childhood eczema [15]. In the current study, no
significant interaction was observed between SNP
rs1800925 and smoking with respect to eczema.
The current study offers two main methodological
advantages: study subjects were homogeneous in that
they were all pregnant women, and adjustment was made
for several confounders. Nevertheless, we could not rule
out residual confounding because of other unknown vari-
ables. It is also subject to several limitations, however:
first, the participation rate cannot be calculated because
the exact number of eligible pregnant women who were
provided with the abovementioned KOMCHS documents
is not available. In addition, we were not able to assess
differences between participants and non-participants,
because information on personal characteristics such as
age, socioeconomic status, and a history of allergic disor-
ders among the non-participants was not available. Our
subjects were probably not a representative sample of
Japanese women in the general population; it can be
shown, for example, that educational levels were higher
in the current study population than in the general popu-
lation. According to the 2000 population census of Japan,
the proportions of women aged 30 to 34 years in
Fukuoka Prefecture with years of education of < 13, 13-
14, ≥ 15, and unknown were 52.0%, 31.5%, 11.8%, and
4.8%, respectively [27]. The corresponding figures for the
current study in the control group were 21.1%, 34.0%,
44.9%, and 0.0%, respectively. Thus the present popula-
tion might have had greater awareness concerning
health-related matters compared to the general popula-
tion. Regardless, the distribution of the 2 SNPs under
study in the control group was in agreement with the
Hardy-Weinberg equilibrium.
The definition of eczema was based on the questions
in the ISAAC questionnaire, although validation tests of
such questions have not been performed for Japanese
young adults. Data on serum-specific IgE levels or skin
prick tests were not available. The possibility of non-dif-
ferential outcome misclassification might have biased
the magnitude of the observed associations toward the
null.
Control subjects were women without eczema as
d e f i n e db yt h eI S A A Cc r i t e r i aw h oh a dn o tb e e nd i a g -
n o s e db yad o c t o rw i t ha t o p i ce c z e m aa n dh a dn oc u r -
rent asthma as defined by the European Community
Respiratory Health Survey. To minimize the effect of
allergic sensitization based on asthma in our cases, we
performed a sensitivity analysis excluding cases with
current asthma: the results of the sensitivity analysis
were similar to those in the overall analysis.
The number of cases was rather small for a valid
genetic association study, but a significant association
with SNP rs1800925 was nevertheless detected.
Correction for multiple testing was not performed in
the current study. As this is a hypothesis testing study
and part of the current findings is a replication of pre-
viously published results, we think that correction for
multiple testing would cause us to underestimate our
results.
Conclusions
The current study suggests that IL13 SNP rs1800925,
but not rs20541, is significantly associated with the risk
of eczema in Japanese young adult women. To our
knowledge, this is the first study to find a significant
association between SNP rs1800925 and eczema in non-
Western adult populations. We could not provide evi-
dence for an interaction between SNP rs1800925 and
smoking with respect to eczema. Additional studies with
a greater number of cases are required to confirm these
findings.
Abbreviations
CI: Confidence interval; ISAAC: International Study of Asthma and Allergies in
Childhood; KOMCHS: Kyushu Okinawa Maternal and Child Health Study; OR:
Odds ratio; SNP: single nucleotide polymorphism.
Table 4 Interaction between IL13 rs1800925 polymorphism and smoking
Smoking status
No Yes
SNP No. of cases/controls Adjusted OR (95% CI)* No. of cases/controls Adjusted OR (95% CI)*
CC + CT 119/727 1.00 59/328 1.06 (0.75-1.50)
TT 6/19 1.96 (0.76-5.03) 4/8 2.85 (0.83-9.73)
P for multiplicative interaction = 0.69
Measures of additive interaction
†
Relative excess risk due to interaction (RERI) = 0.83 (95% CI: -3.08-4.74)
Attributable proportion due to interaction (AP) = 0.29 (95% CI: -0.78-1.37)
Synergy index (S) = 1.82 (95% CI: 0.13-24.85)
* Adjusted for age, region of residence, number of children, and education.
† Statistically significant with the 95% CI of RERI > 0, the 95% CI of AP > 0, or the 95% CI of S > 1, indicating additive interaction.
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